Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …

Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …

Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …

Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …

We conducted an extended follow-up study (March 2006–May 2008) to assess the longer
term efficacy of a prophylactic monovalent human papillomavirus (HPV) type 16 L1 virus-like …

Abstract Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV)
L1 virus-like-particle (VLP) vaccine has been shown to be 95%–100% effective in …

OBJECTIVE: Human papillomavirus (HPV) is a necessary cause for cervical cancer, and it
has been associated with vulvar and vaginal cancer and vulvar (VIN) and vaginal (VaIN) …

Background Cervical cancer and its obligate precursors, cervical intraepithelial neoplasia
grades 2 and 3 (CIN2/3), and adenocarcinona in situ (AIS), are caused by oncogenic human …

Background Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will
require a high level of sustained protection against infection and precancerous lesions. Our …

Background The aim of this interim analysis of a large, international phase III study was to
assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate …